1. Scrip
  2. >>Business

Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

Major Deal For ‘Gene Traffic Control’ Company

 
• By Andrew McConaghie

US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.

Cambridge
The Cambridge, MA-based firm has been around since 2016, and came out of 'stealth mode' two years ago

Merck & Co has claimed rights on a promising pipeline of new gene regulating therapies from Foghorn Therapeutics. 

More from Business

More from Scrip